Participant flow

Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma · Source last updated 2016-03-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Patients receive MLN8237 (alisertib) PO BID on days 1-7. Treatment repeats every 21 days for 17 courses in the absence of disease progression or unacceptable toxicity

   id

   FG000

   title

   MLN8237

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         5

      type

      Ineligible

   2. reasons

      1. group Id

         FG000

         num Subjects

         6

      type

      Adverse Event

   3. reasons

      1. group Id

         FG000

         num Subjects

         20

      type

      Progression/relapse

   4. reasons

      1. group Id

         FG000

         num Subjects

         4

      type

      Death

   5. reasons

      1. group Id

         FG000

         num Subjects

         5

      type

      Other reason not protocol specified

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         42

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         37

      type

      Eligible and Treated

   3. achievements

      1. group Id

         FG000

         num Subjects

         2

      type

      COMPLETED

   4. achievements

      1. group Id

         FG000

         num Subjects

         40

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice